Astellas grabs a biotech toddler in $109M buyout deal for a glaucoma gene therapy program
Astellas has snapped up a 3-year-old biotech startup which has been developing a gene therapy for glaucoma.
Launched in 2015, Quethera has been …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
